Clinical Trials Logo

Clinical Trial Summary

This is a Phase III Randomized, Open-Label Clinical Study of Napabucasin (GB201) in Combination with Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Metastatic Pancreatic Cancer Following Front-Line Chemotherapy Failure


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03721744
Study type Interventional
Source 1Globe Biomedical Co., Ltd.
Contact Shirley Yuan
Phone +86-15901044003
Email yuanning@1globe-china.com
Status Recruiting
Phase Phase 3
Start date October 25, 2018
Completion date December 2021

See also
  Status Clinical Trial Phase
Recruiting NCT04753879 - Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. Phase 2
Completed NCT01417000 - Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer Phase 2
Active, not recruiting NCT02975141 - Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer Phase 1
Active, not recruiting NCT00761345 - Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer Phase 1
Completed NCT00919282 - Gemcitabine (GFF) in Patients With Pancreatic Cancer Phase 2
Completed NCT01088815 - Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas Phase 2
Completed NCT04133155 - Retrospective Analysis of 2nd-line Nab-Paclitaxel + Gemcitabine After 1st-line FOLFIRINOX in Pancreatic Cancer
Withdrawn NCT05251038 - Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer Phase 1/Phase 2
Recruiting NCT04612530 - PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer Phase 1
Completed NCT03602885 - EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options N/A
Recruiting NCT05442749 - Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer Phase 2
Recruiting NCT04222413 - Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors Phase 1
Completed NCT03261947 - A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors Phase 2
Withdrawn NCT06017323 - Proglumide With Gemcitabine and Nab-Paclitaxel in PatientsWith Metastatic Pancreatic Ductal Adenocarcinoma Phase 1
Terminated NCT01946646 - Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer Phase 1
Completed NCT01523457 - Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer Phase 2
Active, not recruiting NCT00986661 - A Study to Assess PV-10 Chemoablation of Cancer of the Liver Phase 1
Terminated NCT00726037 - A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer Phase 2
Completed NCT00744640 - Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma Phase 1/Phase 2
Recruiting NCT04589234 - Saltikva for Metastatic Pancreatic Cancer Phase 2